UNSPSC 51392229: Tramazoline hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C13H17N3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4DG710Q678, chemically known as 4,5-dihydro-n-(5,6,7,8-tetrahydro-1-naphthalenyl)-1h-imidazol-2-amine but more generally known as tramazoline hydrochloride, which bears US NIH Compound Identifier 5524. European Medicines Agency schedules Tramazoline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04928MIG.

UNSPSC 51392229 Tramazoline hydrochloride is a Commodity code that in recent state and local procurement activity appears to be tagged for pharmaceutical and medical supply acquisitions, though the single recent opportunity on file involves naloxone and drug deactivation systems rather than tramazoline specifically. State and local health departments, county health agencies, and public health authorities use codes in this pharmaceutical family to procure medications and related health products for community health initiatives, emergency response, and public health programs. The scope of work encompasses the purchase and delivery of pharmaceuticals and medical supplies to support public health operations, with vendors typically responsible for logistics, compliance certifications such as E-Verify and drug-free workplace documentation, and insurance coverage requirements including workers' compensation and commercial general liability.

Seminole County, Florida is the primary recent issuing body on record, having posted IFB 60459723LAS on June 30, 2026, to solicit 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building at 520 West Lake Mary Boulevard, Sanford, Florida. The solicitation closed July 26, 2023, with a two-year initial contract term and one-year renewal option, fixed-fee pricing, and potential FEMA funding that triggers additional federal compliance requirements. The procurement shows limited recent activity under this specific code; bidders should verify that their pharmaceutical product or service aligns with the actual commodity the issuing body needs rather than relying on code classification alone.